These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39558020)

  • 1. Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease.
    Yin J; Zhou X; Li X; Yuan C; Chu X; Hao L; Wu H; Zhong Y
    Sci Rep; 2024 Nov; 14(1):28557. PubMed ID: 39558020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A multicenter, prospective, phaseⅡ, single-arm study on the treatment of newly diagnosed multiple myeloma with domestic bortezomib in combination with lenalidomide and dexamethasone].
    Xie LN; Wang X; He Q; Wang H; Ma J; Zhang HY; Liu N; Jie GT; Xiao TW; Zhang H; Zhang HG; Li ZJ; Xing LJ
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):571-576. PubMed ID: 39134489
    [No Abstract]   [Full Text] [Related]  

  • 3. A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
    Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; Lonergan S; Ahmadi T; Liu Y; Wang J; Vieyra D; van Brummelen EMJ; Vanquickelberghe V; Sitthi-Amorn A; de Boer CJ; Carson R; Rodriguez-Otero P; Bladé J; Moreau P
    Future Oncol; 2024; 20(38):3043-3063. PubMed ID: 39287147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
    Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
    J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
    Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
    Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.
    LeBlanc R; Thiant S; Terra R; Ahmad I; Claveau JS; Bambace N; Bernard L; Cohen S; Delisle JS; Lachance S; Kiss T; Roy DC; Sauvageau G; Roy J
    Curr Oncol; 2024 Nov; 31(11):7258-7274. PubMed ID: 39590165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.
    Voorhees P; Suman V; Efebera Y; Raje N; Tuchman S; Rodriguez C; Laubach J; Bova-Solem M; Carlisle D; Usmani S; McCarthy P; Richardson PG
    Blood Adv; 2024 Oct; 8(19):5039-5050. PubMed ID: 39058954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.
    Gurumurthi A; Chin CK; Feng L; Fowler NH; Strati P; Hagemeister FB; Fayad LE; Westin JR; Obi C; Arafat J; Nair R; Steiner RE; Neelapu SS; Flowers CR; Nastoupil LJ
    EClinicalMedicine; 2024 Aug; 74():102747. PubMed ID: 39161543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
    Badawi MA; Engelhardt B; Dobkowska E; Deng R; Kaufman JL; Menon R; Salem AH
    Invest New Drugs; 2024 Dec; 42(6):635-643. PubMed ID: 39388024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.
    Tilmont R; Yakoub-Agha I; Eikema DJ; Zinger N; Haenel M; Schaap N; Arroyo CH; Schuermans C; Besemer B; Engelhardt M; Kuball J; Michieli M; Schub N; Wilson KMO; Bourhis JH; Mateos MV; Rabin N; Jost E; Kröger N; Moraleda JM; Za T; Hayden PJ; Beksac M; Mclornan D; Schönland S; Manier S
    Bone Marrow Transplant; 2023 Nov; 58(11):1182-1188. PubMed ID: 37543712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
    Borchmann P; Ferdinandus J; Schneider G; Moccia A; Greil R; Hertzberg M; Schaub V; Hüttmann A; Keil F; Dierlamm J; Hänel M; Novak U; Meissner J; Zimmermann A; Mathas S; Zijlstra JM; Fosså A; Viardot A; Hertenstein B; Martin S; Giri P; Scholl S; Topp MS; Jung W; Vucinic V; Beck HJ; Kerkhoff A; Unger B; Rank A; Schroers R; Zum Büschenfelde CM; de Wit M; Trautmann-Grill K; Kamper P; Molin D; Kreissl S; Kaul H; von Tresckow B; Borchmann S; Behringer K; Fuchs M; Rosenwald A; Klapper W; Eich HT; Baues C; Zomas A; Hallek M; Dietlein M; Kobe C; Diehl V; ; ; ; ;
    Lancet; 2024 Jul; 404(10450):341-352. PubMed ID: 38971175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
    Voorhees PM; Sborov DW; Laubach J; Kaufman JL; Reeves B; Rodriguez C; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Bumma N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Dinner S; Gries KS; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG
    Future Oncol; 2024 Oct; ():1-25. PubMed ID: 39452950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM).
    Batinić J; Dreta B; Rinčić G; Mrdeža A; Jakobac KM; Krišto DR; Vujčić M; Piršić M; Jonjić Ž; Periša V; Sinčić Petričević J; Coha B; Holik H; Valković T; Stanić M; Krečak I; Stojanović A; Sajfert D; Bašić-Kinda S
    Medicina (Kaunas); 2024 Nov; 60(11):. PubMed ID: 39597090
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
    Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
    [No Abstract]   [Full Text] [Related]  

  • 18. Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.
    Leypoldt LB; Tichy D; Besemer B; Hanel M; Raab MS; Mann C; Munder M; Reinhardt HC; Nogai A; Gorner M; Ko YD; de Wit M; Salwender H; Scheid C; Graeven U; Peceny R; Staib P; Dieing A; Einsele H; Jauch A; Hundemer M; Zago M; Pozek E; Benner A; Bokemeyer C; Goldschmidt H; Weisel KC
    Future Oncol; 2024 Dec; 20(39):3193-3207. PubMed ID: 39345094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.
    Maruyama D; Jacobsen E; Porcu P; Allen P; Ishitsuka K; Kusumoto S; Narita T; Tobinai K; Foss F; Tsukasaki K; Feldman T; Imaizumi Y; Izutsu K; Morishima S; Yamauchi N; Yuda J; Brammer JE; Kawamata T; Ruan J; Nosaka K; Utsunomiya A; Wang J; Zain J; Kakurai Y; Yamauchi H; Hizukuri Y; Biserna N; Tachibana M; Inoue A; Horwitz SM
    Lancet Oncol; 2024 Dec; 25(12):1589-1601. PubMed ID: 39486432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.